Sanofi rolls out generic of its RA med Arava; Former Merck scientist shares Nobel;

@FiercePharma: Something's got to give in India's pharma policy contradictions. More | Follow @FiercePharma

@EricPFierce: AmerisourceBergen injects itself into compounding industry with $2.5B deal for PharMEDium. Article | Follow @EricPFierce

@CarlyHFierce: Payers want new guidelines, more data before easing access to diabetes' CV star Jardiance. Story | Follow @CarlyHFierce

> Sanofi ($SNY) launched an authorized generic version of its own rheumatoid arthritis drug Arava (leflunomide), which blocks autoimmune antibodies to reduce symptoms but also slow down RA-related joint damage. Report

> A former Merck & Co. ($MRK) scientist is sharing the Nobel Prize in medicine for helping discover treatments for two parasitic diseases that plague the developing world. Report

> India's foreign secretary says the European Union's ban on his country's generic drugs is "unwarranted" and a obstacle to current trade talks. Report

> Alvogen bought Russian rights to five hormonal branded products from Bayer, including the hormone replacement Klimonorm and contraceptive Triquilar. Release

Medical Device News

@FierceMedDev: Cancer Genetics makes strides in $14M deal for Response Genetics. FierceDiagnostics article | Follow @FierceMedDev

@EmilyWFierce: ICYMI: Want to get a warning letter from OPDP? Omit drug risks from your promos. More from FiercePharmaMarketing | Follow @EmilyWFierce

> Baxter, Boston Sci back TVA in $15M round to ease hemodialysis vascular access. Story

> FDA orders postmarket studies from trio of duodenoscope makers as 'superbug' scare continues. Article

Biotech News

@FierceBiotech: After a $191M IPO, Adaptimmune buys a new cancer R&D outpost. More | Follow @FierceBiotech

@JohnCFierce: Sold out the Fierce London biotech conference, which is cool. Thank you, UK. Event | Follow @JohnCFierce

@DamianFierce: Yes, good fun, my hip-hop peers, but what's REALLY wack is chronic obstructive pulmonary disease. | Follow @DamianFierce

> Take the poll: Has the biotech boom come to an end? Poll

> Axovant rolls into Phase III with a risky Alzheimer's gambit. More

Drug Delivery News

> Perrigo licenses Flamel's oral suspension delivery platform to develop additional OTC meds. More

> Novel catheter designed for rectal drug delivery wins CE mark. Article

> GSK obtains rights to inhaled nanoparticles made using Liquidia's PRINT platform. News

> Genisphere snags $4M to move its 3DNA platform into the clinic. Story

> Polymer microneedles embedded with cancer drugs degrade to treat skin carcinomas. More

Pharma Manufacturing News

> AmerisourceBergen lays out $2.5B for sterile compounder PharMEDium. Article

> Baxter recalls more saline, this time for potential mold contamination. Report

> India intends to establish drug testing labs in effort to boost quality. Item

> Hospira recalls more lidocaine with rust embedded in vials. Story

> Pfizer adding jobs to Ireland plant that had been slated to close. Article

Pharma Asia News

> JHL Biotech tests the waters on Taiwan's Emerging Stock Board. Item

> Something's got to give in India's pharma policy contradictions. More

> India considers drug testing labs in each state. Report

> TPP negotiators said to reach compromise on biologics. Story

> Japanese flu vaccine makers pump up prices 50%, drawing flak as peak season hits. Article

And Finally... San Francisco's aggressive approach to HIV testing and treatment has helped clamp down on new cases in the city. Report

Suggested Articles

An oncologist leader RBC Capital Markets interviewed expressed comfort that Trodelvy will succeed in earlier-line TNBC and in HR-positive disease.

Gilead Sciences is the latest drugmaker to settle Justice Department claims that its charity contributions were actually kickbacks.

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.